Please assess the completion status of the following clinical trial:

Trial Title: Study of the Efficacy and Safety of Ferrlecit in the Maintenance Dosing in Hemodialysis Patients.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male of female, 18 years old or older.~* Have been receiving chronic hemodialysis therapy~* On stable EPO dosing regimen.~* Have signed patient informed consent.~* Predetermined serum ferritin and TSAT levels.~* Clinical instability - inability to achieve adequate dialysis, abnormal serum albumin and serum glucose.~* Pregnant or lactating.~* A known sensitivity to Ferrlecit~Exclusion Criteria:~* Scheduled for renal transplant.~* A serious concomitant medical disorders incompatible with participation in the study.~* Unable to cooperate or comply with the protocol.~* Use of any investigation agent within 30 days prior to study or during the course of the study.~* Judged by the investigator as unsuitable for enrollment for any reason.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Oral Iron
- 2 (Type: EXPERIMENTAL): sodium ferric gluconate
- 3 (Type: EXPERIMENTAL): sodium ferric gluconate

Based on this trial design, predict the completion outcome and termination type (if applicable).